Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury
NSARF
1 other identifier
observational
200
1 country
1
Brief Summary
The purpose of this study is to determine soluble HJV could be an early diagnosis urinary biomarker of ischemia/reperfusion injury in post CPB-patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
January 2, 2012
CompletedFirst Posted
Study publicly available on registry
January 4, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2012
CompletedJanuary 4, 2012
July 1, 2011
2 months
January 2, 2012
January 3, 2012
Conditions
Keywords
Eligibility Criteria
patients (cases) that developed AKI during the follow-up period of 72 h. AKI was defined as a 50% or greater increase in SCr from baseline according to the RIFLE-R criteria. For each of these cases, we then selected 20 controls from patients who also underwent open heart surgery but did not develop AKI. We matched the cases and controls as closely as possible for age, sex, baseline estimated GFR, comorbidities, medications, type of surgery and perioperative complications.
You may qualify if:
- AKI is defined as a serum creatinine level greater that 50% more than baseline during the first 3 postoperative days (PODs), and non-AKI, as a less than 10% increase.
You may not qualify if:
- Patients with chronic kidney disease (baseline estimated glomerular filtration rate \< 60 mL/min/1.73 m2 as calculated by using the 4-variable Modification of Diet in Renal Disease Study equation, or protein-creatinine ratio \> 100 mg/mmol) are excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wen-Je Ko
Taipei, Taiwan, 10002, Taiwan
Biospecimen
Blood samples are drawn before the first dialysis session after postcardiac sugary associated severe AKI ( initializing RRT). Blood is drawn into Vacutainer tubes containing EDTA, and immediately placed on ice and centrifuged within 1 h. All the samples are stored at -70°C until analysis.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
V C Wu, M.D., Ph.D.
Section of Nephrology, Department of Internal Medicine, National Taiwan University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 2, 2012
First Posted
January 4, 2012
Study Start
June 1, 2011
Primary Completion
August 1, 2011
Study Completion
July 1, 2012
Last Updated
January 4, 2012
Record last verified: 2011-07